GCM
VIR icon

Gladius Capital Management’s Vir Biotechnology VIR Stock Holding History

Gladius Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,794
Closed -$38.4K – 372
2024
Q1 		$38.4K Buy
+3,794
New +$38.6K 0.01% 225
2023
Q4 		– Sell
-2,111
Closed -$19.8K – 419
2023
Q3 		$19.8K Buy
+2,111
New +$30.1K ﹤0.01% 340
2023
Q2 		– Sell
-1,216
Closed -$28.3K – 467
2023
Q1 		$28.3K Sell
1,216
-148
-11% -$3.79K ﹤0.01% 294
2022
Q4 		$34.5K Sell
1,364
-165
-11% -$4.04K ﹤0.01% 283
2022
Q3 		$30K Buy
+1,529
New +$38.9K ﹤0.01% 312

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Gladius Capital Management's VIR Position: Q2 2024 in Review

Gladius Capital Management sold out of Vir Biotechnology (VIR) in Q2 2024, closing a stake of 3,794 shares — an estimated $38.4K sold.

Gladius Capital Management first reported a position in VIR in Q3 2022 and held it in 5 quarters. The position peaked at $38.4K in Q1 2024. 215 funds tracked by Wall St. Rank hold VIR as of Q2 2024.

  • Gladius Capital Management reported no remaining Vir Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Gladius Capital Management sold 3,794 Vir Biotechnology shares in Q2 2024, an estimated $38.4K.
  • Gladius Capital Management first reported a position in Vir Biotechnology in Q3 2022 and held it in 5 quarters.
  • Gladius Capital Management's Vir Biotechnology position peaked at $38.4K in Q1 2024.
  • 215 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2024.

Based on Gladius Capital Management's 13F filing for Q2 2024, filed 18 Jul 2024.